Some GLP-1s Achieve More Weight Loss Than Others: Study By Dennis Thompson HealthDay ... shows that the widely-known drugs tirzepatide (Zepbound) and semaglutide (Wegovy) are both safe and ...

© 2024 Fortune Media IP Limited. All Rights Reserved. Use of this site constitutes acceptance of our Terms of Use and Privacy Policy | CA Notice at Collection and ...

As Eli Lilly ends the year with Zepbound in good supply, TD Cowen analyst Steve Scala asked CEO David Ricks if the company ...

Eli Lilly investors and analysts said they want to hear details from the company on how exactly it plans to grow U.S. sales ...

but still less than what’s been seen with competitor Eli Lilly’s Zepbound. In a 72-week study, a 7.2-milligram dose of Wegovy led patients with obesity to lose 18.7% of their weight ...

News research shows GLP-1 medications may help treat a wide range of conditions, from addiction and dementia to heart disease ...

Zepbound (tirzepatide ... resulted in significant and sustained weight loss. The study, which had support from the drug’s manufacturer, found that tirzepatide resulted in a mean total body ...

Eli Lilly (NYSE: LLY) has underperformed broader equities. While that's not much of an issue in the grand scheme of things, ...

Novo Nordisk is under pressure from investors for more information about its next-generation obesity drug candidate CagriSema ...

Drugmakers have poured small fortunes into the development of weight loss medicines in the past few years in attempts to lead ...

More than 69.2 million FDA-approved weight-loss prescriptions were dispensed in the U.S. from July 2017 through February 2024 ...